BridgeBio Pharma, Inc. (BBIO) Institutional Ownership & Insider Trading

474 institutions reported holding BridgeBio Pharma, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 154 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

BBIOBridgeBio Pharma, Inc.Follow BBIO — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 13.4B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 29 Oct, in 5 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

474 institutions held 99.1% of the shares. Across filers that reported both quarters, shares held changed -2.5%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	474	194	-2.5%	158	67	151	57
Mar 26	455	194	+5.0%	169	66	123	43
Dec 25	427	188	+0.1%	144	67	128	39
Sep 25	383	185	-0.2%	136	62	123	29
Jun 25	356	189	+0.9%	127	82	97	29
Mar 25	301	185	+5.6%	109	63	69	27
Dec 24	260	177	+1.1%	96	31	70	33
Sep 24	249	171	-2.7%	100	33	65	31

BridgeBio Pharma, Inc. — questions

Who owns BridgeBio Pharma, Inc. stock?: 474 institutions reported BridgeBio Pharma, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: Jupiter Topco LLC (7.2%), Kohlberg Kravis Roberts & Co. L.P. (6.8%), FARALLON CAPITAL MANAGEMENT LLC (5.5%).
Are BridgeBio Pharma, Inc. insiders buying or selling?: 154 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from BridgeBio Pharma, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.